Oncotelic Therapeutics (OTLC) CEO Vuong Trieu Buys $3.2K of Stock
Chairman and CEO Vuong Trieu buys 65,000 shares of Oncotelic Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
Vuong Trieu, CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. ($OTLC), bought 65,000 shares at an average price of $0.05, worth about $3,250, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OTLC is down 20.0% after 1 week, down 20.0% after 1 month and down 60.0% to date (from the $0.05 close on Jun 22, 2026).
OTLC
Oncotelic Therapeutics, Inc.
Key Points
- Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, bought 65,000 shares on June 22, 2026, at $0.05 each.
- Oncotelic Therapeutics trades on the OTC Markets OTCQB with a market cap of about $22.2 million and a P/E ratio of 0.08.
- Recent insider transactions include multiple purchases by Vuong Trieu and CFO Amit Shah, reflecting ongoing insider interest.
Get $OTLC trade alerts by text
We text you when insiders, Congress or big funds trade $OTLC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Oncotelic Therapeutics, Inc. alert may contain errors. Disclosures
On June 22, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), acquired 65,000 shares of the company. The shares were purchased at $0.05 each, amounting to a $3,250 transaction. This was not part of a planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
Recent insider activity at Oncotelic Therapeutics shows a series of purchases by its top executives. Vuong Trieu has been actively buying shares, with transactions on June 24, June 23, and June 17, 2026, totaling over 400,000 shares in recent weeks. Additionally, Amit Shah, the CFO, bought 20,000 shares on June 22, 2026, at the same price. None of these purchases were under pre-arranged trading plans, indicating a strong personal interest in the company's stock.
Oncotelic Therapeutics, Inc. Stock Up 100.0%
Shares of Oncotelic Therapeutics traded around $0.05 on Thursday. The company has a market capitalization of approximately $22.2 million. It boasts a P/E ratio of 0.08, reflecting its low earnings relative to its share price. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company's beta is -0.317, suggesting it moves inversely to the overall market.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Agoura Hills, California. It focuses on developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer treatment. Key projects include OT-101 for pancreatic cancer and OXi4503 for acute myeloid leukemia. The company, led by CEO Dr. Vuong Trieu, employs 38 people.
Bottom Line
Vuong Trieu's recent purchase of Oncotelic Therapeutics shares highlights his confidence in the company's future. Insider buying can sometimes signal positive expectations from those with intimate knowledge of the company. However, investors should remember that these transactions are disclosed after they occur and reflect past actions, not current intentions.
Related Filing Alerts
Source: Vuong Trieu's Form 4 filing on $OTLC (Jun 22, 2026). Find the original filing: OTLC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts